Tongjitang Chinese Medicines Company to Announce Fourth Quarter and Full Year 2009 Financial Results on March 31, 2010

News provided by

Tongjitang Chinese Medicines Company

Mar 01, 2010, 08:00 ET

SHENZHEN, China, March 1 /PRNewswire-Asia-FirstCall/ -- Tongjitang Chinese Medicines Company (the "Company" or "Tongjitang") (NYSE: TCM), a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced that it plans to announce its fourth quarter and full year 2009 financial results before the market opens on Wednesday, March 31, 2010.

Tongjitang's management team will hold a conference call on March 31 at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing/Hong Kong time) following the announcement. Listeners may access the call by dialing the following numbers:

    United States toll free:  1-888-228-5279
    Hong Kong toll free:      800 903 658
    Northern China toll free: 10 800 7141504
    Southern China toll free: 10 800 1401379
    International:            1-913-312-1429

Listeners may access the replay through April 7, 2010, by dialing the following numbers:

    United States toll free:  1-888-203-1112
    International:            1-719-457-0820
    Password:                 1164592

An audio webcast of the call will also be available through the Company's website at http://www.tongjitang.com .

About Tongjitang Chinese Medicines Company

Tongjitang Chinese Medicines Company, through its operating subsidiaries Tongjitang Pharmaceutical, Tongjitang Distribution, Tongjitang Chain Stores, Guizhou Long-Life Pharmaceutical Company Limited, Qinghai Pulante and Anhui Jingfang, is a vertically integrated specialty pharmaceutical company focused on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China. Tongjitang's principal executive offices are located in Shenzhen, China.

Tongjitang's flagship product, Xianling Gubao, is the leading traditional Chinese medicine for the treatment of osteoporosis in China as measured by sales in Renminbi. In addition to Xianling Gubao, the Company manufactures and markets 36 other modernized traditional Chinese medicine products and 37 western medicines. Please visit http://www.tongjitang.com for more information.

    For more information, please contact:

    ICR, Inc.
     Ashley M. Ammon or Christine Duan
     Tel: +1-203-682-8200 (Investor Relations)

SOURCE Tongjitang Chinese Medicines Company

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED